# US 2026/0076958 A1 · Liquid formulations of indacaterol

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0076958 A1
- Document ID: US20260076958A1
- Status: Published application
- Kind: A1
- Application number: 19/315,294
- Filed: 2025-08-29
- Published: 2026-03-19
- Earliest claimed: 2020-09-29
- Assignees: Aerorx Therapeutics LLC
- Applicants: AeroRx Therapeutics, Inc.
- Inventors: John CHAN; Keith Try UNG; Mei-Chang KUO; John Nigel PRITCHARD
- Web page: https://patentgrep.com/patent/US20260076958A1

## CPC

- A61K 31/4704: 2-Quinolinones, e.g. carbostyril
- A61K 9/0078: {for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 9/12: Aerosols; Foams {(A61K9/0043, A61K9/0056, A61K9/006, A61K9/0073 take precedence; spray-films A61K9/7015)}
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/5386: spiro-condensed or forming part of bridged ring systems
- A61K 31/58: containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin (digitoxin {A61K31/7048})
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/6951: {using cyclodextrin (cyclodextrins used as simple excipients A61K47/40)}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Aqueous formulations of indacaterol are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

An aqueous pharmaceutical composition comprising:
from about 20 weight percent to 99.9 weight percent water;
indacaterol, or a pharmaceutically acceptable salt thereof, present at a concentration of 10 μg/mL to 2 mg/mL;
glycopyrrolate, or a pharmaceutically acceptable salt thereof, present at a concentration of about 10 μg/mL to 2 mg/mL,
two or more tonicity modifiers; and
a buffer,
wherein the indacaterol is present as a free base or as a pharmaceutically acceptable salt thereof without the presence of maleic acid from a maleate salt in the aqueous pharmaceutical composition, and
wherein the aqueous pharmaceutical composition has a pH from 3 to 5.

### Claim 22 (depends on 21)

The pharmaceutical composition of claim 21, wherein the indacaterol, or a pharmaceutically acceptable salt thereof, is present at a concentration of 10 μg/mL to 200 μg/mL.

### Claim 23 (depends on 21)

The pharmaceutical composition of claim 21, wherein one of the two or more tonicity modifiers is present at a concentration of about 100 mM to about 500 mM.

### Claim 24 (depends on 21)

The pharmaceutical composition of claim 21, wherein one or the two tonicity modifiers is sodium chloride.

### Claim 25 (depends on 21)

The pharmaceutical composition of claim 21, wherein the buffer comprises an anion selected from the group consisting of acetate, bromide, chloride, citrate, furoate, fumarate, propionate, succinate, sulfate, tartrate, and xinafoate.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein the anion of the buffer in the aqueous pharmaceutical composition is citrate.

### Claim 27 (depends on 21)

The pharmaceutical composition of claim 21, wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of citric acid and sodium hydroxide.

### Claim 28 (depends on 21)

The pharmaceutical composition of claim 21, wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of citric acid and trisodium citrate.

### Claim 29 (depends on 25)

The pharmaceutical composition of claim 25, wherein the anion of the buffer in the aqueous pharmaceutical composition is acetate.

### Claim 30 (depends on 21)

The pharmaceutical composition of claim 21, wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of acetic acid and sodium hydroxide.

### Claim 31 (depends on 21)

The pharmaceutical composition of claim 21, wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of acetic acid and sodium acetate.

### Claim 32 (depends on 25)

The pharmaceutical composition of claim 25, wherein the anion of the buffer in the aqueous pharmaceutical composition is tartrate.

### Claim 33 (depends on 21)

The pharmaceutical composition of claim 21, wherein the aqueous pharmaceutical composition has a pH from 3.5. to 4.5.

### Claim 34 (depends on 21)

The pharmaceutical composition of claim 21, wherein the glycopyrrolate, or a pharmaceutically acceptable salt thereof, is glycopyrronium bromide.

### Claim 35 (depends on 21)

The pharmaceutical composition of claim 21, wherein the glycopyrrolate, or a pharmaceutically acceptable salt thereof, is present in the aqueous pharmaceutical composition at a concentration in a range from about 50 μg/mL to about 200 μg/mL.

### Claim 36 (depends on 21)

The pharmaceutical composition of claim 21, wherein the concentration of the indacaterol in the aqueous pharmaceutical composition is between about 50 μg/mL to about 200 μg/mL; and the concentration of the glycopyrrolate, or a pharmaceutically acceptable salt thereof, in the aqueous pharmaceutical composition is between about 50 μg/mL to about 200 μg/mL.

### Claim 37 (depends on 21)

The pharmaceutical composition of claim 21, further comprising an inhaled corticosteroid.

### Claim 38 (depends on 21)

The pharmaceutical composition of claim 21, wherein the aqueous pharmaceutical composition does not comprise ethanol or a cyclodextrin.

### Claim 39 (depends on 21)

A kit comprising
the pharmaceutical composition of claim 21; and
a device for aerosolizing the pharmaceutical composition.

### Claim 40 (depends on 39)

The kit of claim 39, wherein the device is selected from the group consisting of a jet nebulizer and a vibrating mesh nebulizer.
